BridgeBio Sees $25 Million To $30 Million Quarterly Gains For Attruby, After $31 Million Step

Management says Attruby's sequential gains should hold near that range for now, and argues swings in launch revenue matter little for peak sales.

Share
BridgeBio Sees $25 Million To $30 Million Quarterly Gains For Attruby, After $31 Million Step

BridgeBio Pharma, which develops medicines for genetic diseases, put a range on the growth of its heart drug Attruby: Chief Business Officer Chinmay Shukla said on the company's earnings call Thursday that "25 to 30 million is the right number near term" for quarterly sales gains, with more to come later. He was answering an Evercore ISI analyst who noted that Attruby's U.S. net product revenue rose about $31 million from the prior quarter to $253.2 million.

Growth, and why swings are noise

Attruby revenue rose approximately 14% from the second quarter and approximately 134% from a year earlier, CEO Neil Kumar said. Total third-quarter revenue was $353.2 million, against $120.7 million a year earlier, CFO Tom Trimarchi said, including a one-time $75 million sales milestone from Bayer for the drug's European version.

Kumar argued that quarterly updates carry real information for a launch, citing the company's modeling of some 1,040 launches. But he said brands that ended up above $3 billion in sales showed on average a 20% quarter-to-quarter variance in the early years that did not meaningfully change projected peak-year sales.

He said Attruby is annualizing at over $1 billion in the U.S. Growth is now mostly from first-line new starts, he said, and over 60% of prescribers, mainly lower-volume and often non-cardiology specialists, have yet to try it. Kumar said to expect the company to pursue them. He also said Pfizer's numbers are needed to understand share.

Payers, cash and the loss line

Asked about a large payer restricting a competing drug, Chief Commercial Officer Matt Outen said he assumed the analyst meant United. He said United made no change to Attruby in 2026, though it moved in mid-2025 to prefer Vyndamax, and that approval rates through appeal are over 90%. Gross-to-net has been stable, he said, and persistency is strong.

Trimarchi said the company had $1.5 billion in cash and marketable securities as of September 30, and reported an $11.6 million operating loss against $145.2 million a year earlier. Operating expenses were $344.4 million, and he expects them to catch up in the fourth quarter. He said all four brands could be profitable on their own by 2028.

Three launches in seven months

BridgeBio faces FDA decision dates of November 27 for BBP418 in a form of limb-girdle muscular dystrophy, February 4, 2027 for infigratinib in achondroplasia, and May 8, 2027 for encaleret in ADH1, all under priority review. Kumar said BridgeBio has three launches ahead in the next seven months.

The next marker is the fourth quarter, when Attruby's gain can be set against the $25 million to $30 million range, and Pfizer's numbers, which Kumar said would clarify share.

Sources

More on BridgeBio Pharma

All BridgeBio Pharma (BBIO) coverage →